Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease.
Twenty-one patients with primary humoral immunodeficiency were treated for 1 year with a chemically intact immunoglobulin, 300 mg/kg body weight given intravenously every 3 weeks, to compare immunoglobulin levels and clinical status with results achieved after standard treatment with intramuscular immunoglobulin given previously for 1 year. A substantial reduction of specific acute illnesses and antibiotic use was found for 18 of the 21 patients, particularly during the second 6 months of treatment. Average IgG levels before intravenous infusion were increased 243 mg/dL over previous intramuscular pre-injection levels. Adverse effects were recorded for 2.5% of infusions.
D000041:Absenteeism; D000293:Adolescent; D000328:Adult; D000368:Aged; D000917:Antibody Formation; D002648:Child; D005260:Female; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D007074:Immunoglobulin G / Q000032:analysis; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000276:immunology / Q000628:therapy*; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D005719:gamma-Globulins / Q000008:administration & dosage* / Q000009:adverse effects
D007074:Immunoglobulin G; D005719:gamma-Globulins